NCT04665648CompletedPhase 4
Clinical Efficacy and sAfety of Intravenous Infusion of Nicorandil During Primary Percutaneous Coronary Intervention
Impact of Intravenous Administration of Nicorandil as Adjuncts to Reperfusion Treatment for Acute ST Segment Elevation Myocardial Infarction: a Multi-center Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 11 Mar 2025
Brief summary (registry, in English)
The investigators evaluate the efficacy and safety of intravenous administration of nicorandil as adjuncts to reperfusion treatment in acute ST-segment elevation acute myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI).
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 1500 (actual)
- First submitted
- 2 Dec 2020
- Start date
- 1 Jun 2021
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Fudan University
- Diseases
- Coronary artery disease
- NCT number
- NCT04665648
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 1500
- From 1 Jun 2021 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- cardiac shock;
- history of myocardial infarction or percutaneous coronary intervention or coronary artery bypass grafting (\<6 month);
- history of the treatment of nicorandil (\<6 month);
- history of intravenous nitrates before percutaneous coronary intervention;
Other
- systolic blood pressure\<100mmHg;
- aortic dissection;
- contraindicated or intolerable to nicorandil;
- pregnant or lactation period;
- patients with an estimated survival time of less than 1 year.
Who the study is looking for
- 18-80 years;
- acute ST-segment elevation myocardial infarction within 12 hours of symptom onset;
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhongshan Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
Related publications
- Intravenous Nicorandil in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary PCI: The CLEAN Randomized Clinical Trial.J Am Coll Cardiol · 2026 · PMID 42584383
This page is information, not medical advice. Discuss any trial with your doctor.